Journal of Developing Drugs
Open Access
ISSN: 2329-6631
+44 1478 350008
ISSN: 2329-6631
+44 1478 350008
Nigel Cryer
NextPharma (EU), UK
Posters & Accepted Abstracts: J Develop Drugs
GMP regulations and guidance often change, but the recent requirement to provide toxicological evaluations of products used in non-dedicated facilities so as to determine that the level of cross contamination minimises the potential for impact on patients, have put the pharmaceutical industry under severe pressure when companies attempt to fully comply with the guidence. As an example, companies who have made products for over 20 years in the same facility are now required to undertake extensive evaluations of these products within 12 months for medicinal products. This presentation explains the regulations and describes a criticality based and pragmatic approach to provide compliance with the regulation. How to deal with new EU requirments for setting health based exposure limits and thereby minimising cross contamination in shared facilities was described in EudraLex â?? â??Volume 4 Good manufacturing practice (GMP) Guidelines Chapter 3 and 5â?. EMA â??Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilitiesâ? (EMA/CHMP/ CVMP/ SWP/169430/2012 Committee for Medicinal Products for Human Use (CHMP) Effective date 01 June 2015). When different medicinal products are produced in shared facilities, the potential for crosscontamination is a concern. Medicinal products provide a benefit to the intended patient or target animal; however as a cross contaminant, they provide no benefit to the patient or target animal and may even pose a risk. Hence, the presence of such contaminants should be managed according to the risk posed which in turn are related to levels that can be considered safe for all populations. To this end, health based limits through the derivation of a safe threshold value should be employed to identify the risks posed. The derivation of such a threshold value (e.g. permitted daily exposure (PDE) or threshold of toxicological concern (TTC)) should be the result of a structured scientific evaluation of all available pharmacological and toxicological data including both non-clinical and clinical data. Deviation from the main approach highlighted in this guideline to derive such safe threshold levels could be accepted if adequately justified.
Email: nigel.cryer@yahoo.co.uk